119 related articles for article (PubMed ID: 38211405)
21. Conditional survival of trimodal therapy for nonmetastatic muscle-invasive bladder cancer: A SEER database analysis.
Shangguan W; Hu J; Xie Y; Chen Z; Zhong Q; Zheng Z; Zhu D; Zhang Y; Yang J; Han J; Xie W
Cancer Med; 2022 Jun; 11(12):2356-2365. PubMed ID: 35301806
[TBL] [Abstract][Full Text] [Related]
22. Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917).
Nakayama T; Yoshinami T; Yasojima H; Kittaka N; Takahashi M; Ohtani S; Kim SJ; Kurakami H; Yamamoto N; Yamada T; Takata T; Masuda N
BMC Cancer; 2021 Jul; 21(1):795. PubMed ID: 34238257
[TBL] [Abstract][Full Text] [Related]
23. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
[TBL] [Abstract][Full Text] [Related]
24. Conditional Survival After Cytoreductive Surgery with Heated Intraperitoneal Chemotherapy for Low- and High-Grade Appendiceal Primaries.
Mogal HD; Levine EA; Russell G; Shen P; Stewart JH; Votanopoulos KI
Ann Surg Oncol; 2016 Feb; 23(2):534-8. PubMed ID: 26289808
[TBL] [Abstract][Full Text] [Related]
25. Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer.
Fabbro M; Colombo PE; Leaha CM; Rouanet P; Carrère S; Quenet F; Gutowski M; Mourregot A; D'Hondt V; Coupier I; Vendrell J; Vilquin P; Pujol P; Solassol J; Mollevi C
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32764409
[No Abstract] [Full Text] [Related]
26. Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer that are non-microsatellite instability high (non-MSI-high) or mismatch repair proficient (pMMR) in the United States.
Kelkar SS; Prabhu VS; Zhang J; Corman S; Macahilig C; Rusibamayila N; Odak S; Duska LR
Gynecol Oncol Rep; 2022 Aug; 42():101026. PubMed ID: 35800987
[TBL] [Abstract][Full Text] [Related]
27. A National Study of Survival Trends and Conditional Survival in Nasopharyngeal Carcinoma: Analysis of the National Population-Based Surveillance Epidemiology and End Results Registry.
Lv JW; Huang XD; Chen YP; Zhou GQ; Tang LL; Mao YP; Li WF; Lin AH; Ma J; Sun Y
Cancer Res Treat; 2018 Apr; 50(2):324-334. PubMed ID: 28421724
[TBL] [Abstract][Full Text] [Related]
28. Early Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Breast Cancer Treated with Eribulin After Prior Immuno-Oncology or Antibody-Drug Conjugate Therapy.
Goyal RK; Zhang J; Davis KL; Sluga-O'Callaghan M; Kaufman PA
Breast Cancer (Dove Med Press); 2023; 15():855-865. PubMed ID: 38020049
[TBL] [Abstract][Full Text] [Related]
29. Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer.
Khozin S; Miksad RA; Adami J; Boyd M; Brown NR; Gossai A; Kaganman I; Kuk D; Rockland JM; Pazdur R; Torres AZ; Zhi J; Abernethy AP
Cancer; 2019 Nov; 125(22):4019-4032. PubMed ID: 31381142
[TBL] [Abstract][Full Text] [Related]
30. Conditional survival nomogram for monitoring real-time survival of young non-metastatic nasopharyngeal cancer survivors.
Luo J; Hu X; Ge X
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10181-10188. PubMed ID: 37266664
[TBL] [Abstract][Full Text] [Related]
31. Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time.
Ploussard G; Shariat SF; Dragomir A; Kluth LA; Xylinas E; Masson-Lecomte A; Rieken M; Rink M; Matsumoto K; Kikuchi E; Klatte T; Boorjian SA; Lotan Y; Roghmann F; Fairey AS; Fradet Y; Black PC; Rendon R; Izawa J; Kassouf W
Eur Urol; 2014 Aug; 66(2):361-70. PubMed ID: 24139235
[TBL] [Abstract][Full Text] [Related]
32. Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer.
Danesi V; Massa I; Foca F; Delmonte A; Crinò L; Bronte G; Ragonesi M; Maltoni R; Manunta S; Cravero P; Andrikou K; Priano I; Balzi W; Gentili N; Burke T; Altini M
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139641
[TBL] [Abstract][Full Text] [Related]
33. Real-world Outcomes Associated With Poly(ADP-ribose) Polymerase Inhibitor Monotherapy Maintenance in Patients With Primary Advanced Ovarian Cancer.
Chan JK; Liu J; Song J; Xiang C; Wu E; Kalilani L; Hurteau JA; Thaker PH
Am J Clin Oncol; 2023 Jul; 46(7):314-322. PubMed ID: 37106485
[TBL] [Abstract][Full Text] [Related]
34. Conditional survival analysis and real-time prognosis prediction for cervical cancer patients below the age of 65 years.
Meng X; Jiang Y; Chang X; Zhang Y; Guo Y
Front Oncol; 2022; 12():1049531. PubMed ID: 36698403
[TBL] [Abstract][Full Text] [Related]
35. A Multicenter Study Assessing the Real-World Use and Effectiveness of First-Line Chemotherapy Plus Immunotherapy in Advanced Small-Cell Lung Cancer (SCLC) Patients.
Porte M; Vaudron A; Crequit P; Vaugier L; Chatellier T; Fronteau C; Raimbourg J; Goronflot T; Bennouna J; Pons-Tostivint E
Clin Lung Cancer; 2024 Mar; 25(2):e101-e111.e2. PubMed ID: 38072729
[TBL] [Abstract][Full Text] [Related]
36. Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma.
Zarrabi KK; Handorf E; Miron B; Zibelman MR; Anari F; Ghatalia P; Plimack ER; Geynisman DM
Oncologist; 2023 Feb; 28(2):157-164. PubMed ID: 36200791
[TBL] [Abstract][Full Text] [Related]
37. Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer who are microsatellite instability (MSI)-high or are mismatch repair deficient (dMMR) in the United States.
Kelkar SS; Prabhu VS; Corman S; Odak S; Rusibamayila N; Macahilig C; Orlowski R; Duska L
Gynecol Oncol; 2023 Feb; 169():154-163. PubMed ID: 36344294
[TBL] [Abstract][Full Text] [Related]
38. Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study.
Bhatia S; Nghiem P; Veeranki SP; Vanegas A; Lachance K; Tachiki L; Chiu K; Boller E; Bharmal M
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35981787
[TBL] [Abstract][Full Text] [Related]
39. Conditional Survival of Advanced Epithelial Ovarian Cancer: A Real-World Data Retrospective Cohort Study From the SEER Database.
Zheng P; Zheng P; Chen G
Front Med (Lausanne); 2021; 8():756401. PubMed ID: 34888325
[No Abstract] [Full Text] [Related]
40. Development of a Prognostic Factor Index Among Women With HR
Vidal GA; Carter GC; Gilligan AM; Saverno K; Zhu YE; Price GL; DeLuca A; Smyth EN; Rybowski S; Huang YJ; Schwartzberg LS
Clin Breast Cancer; 2021 Aug; 21(4):317-328.e7. PubMed ID: 33678566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
